JUL 04, 2020 5:53 PM PDT

New mechanism that supports the progression and relapse cancer discovered

Researchers have found a mechanism of a key protein that supports the progression and relapse of cancer. This discovery provides hope for improved treatment options that focus on targeting stem-like cells that are more susceptible to chemotherapy and immunotherapy. Their findings are published in the journal PNAS

"We discovered a mechanism involving MBNL1 protein that predicts several characteristics of cancer such as progression and relapse," said lead author Dr. Debleena Ray, Senior Research Fellow at Duke-NUS' Cancer and Stem Cell Biology (CSCB) program. "We found that MBNL1 protein is present in low amounts in many of the common cancers in the world, including breast, colorectal, stomach, lung and prostate cancers, which when combined account for about 49% of all cancers diagnosed in 2018. This can cause poor overall survival in many of these commonly-occurring cancers."

Source: Pixabay

Cancer is the second-highest leading cause of death globally and cancer cases are on the rise. Professor Patrick Casey, Senior Vice Dean for Research at Duke-NUS, explains why this finding is so critical: 

"Cancer is a global health challenge and Singapore is no exception. This study provides important information about novel targets and biomarkers that are implicated in several major cancers, which could lead to the development of new treatment strategies that can improve the lives of patients."

In addition to the discovery of this mechanism, the team also identified that reversing the mechanism resulted in the inhibition of the JNK protein in cancer cells with low levels of MBNL1. JNK is known to be an established target in certain cancer treatments. 

"While JNK inhibitors have been tested as a cancer drug previously, currently there are no clinical trials for the same. However, if in the future there is a JNK inhibitor against cancer, MBNL1 could be used as a biomarker to select patients for the treatment," said co-corresponding author David Epstein at the Duke-NUS' CSCB program.

The researchers plan to continue their investigations of MBNL1 and JNK involving antisense technology, a tool that is used for the inhibition of gene expression.

Sources: PNAS, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 12, 2021
Cancer
Toxic molecules in flame retardants increase breast cancer risk
MAR 12, 2021
Toxic molecules in flame retardants increase breast cancer risk
New research reported in the February issue of the journal Toxicological Sciences suggests that brominated flame re ...
MAR 30, 2021
Immunology
Single-Cell Technology Exposes Melanoma's Weak Spot
MAR 30, 2021
Single-Cell Technology Exposes Melanoma's Weak Spot
The immune system encompasses a powerful arsenal of weapons against pathogenic threats. But what stops healthy tissues i ...
MAR 29, 2021
Cancer
Modeling metastasis
MAR 29, 2021
Modeling metastasis
Novel research published in Genome Biology investigates the cellular mechanisms at work during cancer metastasis using n ...
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
APR 19, 2021
Cancer
Understanding why pacreatic cancer metastasizes
APR 19, 2021
Understanding why pacreatic cancer metastasizes
New research published in the journal Gastroenterology reports on the mechanisms of metastatic pancreatic cancer cells, ...
MAY 27, 2021
Cancer
Which ovarian cancer patients will be resistant to platinum chemotherapy?
MAY 27, 2021
Which ovarian cancer patients will be resistant to platinum chemotherapy?
Research published in the journal EMBO Molecular Medicine details a novel mechanism that can be used to predict which ep ...
Loading Comments...